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Performing clinical trials can be frustrating at times, and
one of the most exasperating tasks is corresponding with
local research ethics committees. We recently quantified
the delays in responses regarding a protocol amendment,
and found that a substantial proportion of the centres we
dealt with took more than 60 days to approve the
amendment; some took considerably longer [1]. Staff in
our trials centre have to ‘chase’ this information, which
means that they have less time for other tasks;
furthermore, a delay in approval meant a delay to the
implementation of the protocol amendment in those local
centres, which is far from satisfactory.
It was therefore very pleasing to hear that a forthcoming
European Union (EU) directive included a section
specifically stating that decisions by ethics committees
should be given in less than 60 days for new protocols
and 35 days for protocol amendments. Our joy was short-
lived, however, when we realized that other aspects of the
directive might actually increase our workload.
The EU produces many directives – it is the mechanism by
which decisions made centrally can be implemented in the
member states. Directives cover a wide range of human
activity, as can be gleaned from their titles: Food
Supplements, Software Patents, Data Protection, Direct
Marketing, Molecular Farming, Traditional Herbal Medicinal
Products and Mutual Recognition of Professional
Qualifications, to name but a few. The directive that sets a
time limit on research ethics committees is Directive
2001/20/EC [2], entitled the Clinical Trials Directive
(CTD), which aims to harmonize the administration of
clinical trials throughout the EU. Member states are
required to implement the CTD into national legislation by
1 May 2004 (which, incidentally, is the same day that the
EU will grow from 15 to 25 member states).
The CTD itself is a fairly short and general document, and
on first reading it appears to be perfectly logical. It is
during the transposition of the CTD into domestic law
where the devilish details emerge, because the passing of
one law can have knock-on effects on many others. The
CTD has a wide scope, and covers many aspects of the
conduct of clinical trials in the EU on human subjects
(including healthy volunteers participating in phase I
studies) that involve a medicinal product. Ethics
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Running clinical trials in the commercial sector has always been associated with a certain amount of
bureaucracy due to the stringent requirements needed to bring a new drug onto the market.
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committees will be established on a legal basis, and legal
status will be provided for certain procedures. There will
also be legislation to cover the manufacture, import,
labelling and quality assurance of investigational medicinal
products; the creation of a European database of all
clinical trials conducted in the EU; and the provision for
safety monitoring of patients in trials (pharmacovigilance),
including procedures for recording and reporting adverse
drug reactions on another pan-European database.
Adherence to both Good Clinical Practice (GCP) and
Good Manufacturing Practice will be ‘policed’; in the UK
the Medicines and Healthcare products Regulatory Agency
will begin a statutory inspection programme of GCP
compliance. The Medicines and Healthcare products
Regulatory Agency (home page: http://www.mhra.gov.uk)
has been designated as the primary source of authoritative
advice and information on the CTD and associated
legislation.
The basic aims of the CTD are to protect participants in
clinical trials and to ensure that data generated from these
trials are accurate and verifiable, which are important in all
trials. So what is the problem? There are several, but one
of the larger problems is that the CTD does not distinguish
between commercial and noncommercial clinical trials –
that is, between trials that are run primarily to obtain a
marketing authorization for a drug and trials that are run
primarily to answer an important scientific question.
For those of us who have experience of industry-
sponsored clinical trials, the principles of the CTD seem
very sensible; indeed, little of it is truly novel. However,
there seems to be an assumption that industry is using the
best model, and this is not always justified. Take, for
example, the concerns about the practical application of
GCP. Those who have experience of trials sponsored by
the pharmaceutical industry are often frustrated by the
attention to seemingly mindless trivia, and the well
meaning but misguided bureaucracy [3]. Some of the
other difficult areas include the introduction of a
commercial-style approach to trial monitoring and
pharmacovigilance that may not always be appropriate,
particularly where the trial is testing a product that is
already on the market.
Perhaps the academic model is the best model to use.
However, can we honestly say that all academic run
clinical trials have been run to the highest standards? Are
we certain that every trial has been run to protocol, that
the studies have been adequately powered, that all
patients have truly given ‘informed consent’, and that
appropriate mechanisms have always been in place to
deal with the reporting of adverse events? Are we not
aware of questionably run trials whose primary aim seems
to be the generation of a publication for the advancement
of academic careers?
In spite of these problems, let no one forget the important
contributions that have been made by noncommercial
trials. This is perhaps best illustrated by those trials
concerned with breast cancer, the results of which have
saved literally millions of lives, notably trials investigating
the role of tamoxifen in early breast cancer. Special issues
that typify these studies include comparisons of the risks
and benefits of similar interventions (shorter or longer
duration of tamoxifen), investigations of long-term outcomes
(5, 10, 20 years after cessation of therapy), finding new
roles for old drugs, determining efficacy in realistic
settings (pragmatic trials), and comparisons with nondrug
therapy (e.g. surgery and radiotherapy). Such studies
answered very important questions without including a
comparison with a novel drug; few of these studies would
have been sponsored by the pharmaceutical industry.
Indeed, it is the role and definition of ‘sponsor’ that is
causing the most angst for those who run noncommercial
trials. The CTD requires a sponsor to take responsibility
for the initiation, management and/or financing of a trial,
which for commercial trials would normally be a drug
company. In noncommercial trials (particularly multicentre
studies) these responsibilities are often distributed among
many individuals and organizations. For example, the trial
might have been initiated in several centres, managed by a
steering committee and data safety and monitoring
committee, with funding provided by two or three sources.
Many of the institutions currently involved (universities,
hospitals and funding bodies) have categorically stated
that they are unwilling to take on the responsibility of a
sponsor, particularly for centres over which they have no
control. Even institutions that are currently running single
centre studies are unsure of what they will be letting
themselves in for and so have declined to take on the role
of sponsor. Perhaps a compromise could be reached that
allowed for shared responsibility, or a special agency
could be set up at a national (or even European) level to
act nominally as sponsor.
There is a worry that, in order to deal with issues of
sponsorship, pharmacovigilance, and other factors,
noncommercial trials will now require funding to a scale
that approaches that of commercial trials. In industry costs
can be passed on, but this is not an option for
noncommercial trials. So who will pay – the government
(unlikely) or industry? Although there are precedents for
industry–academia collaborative ventures (e.g. ATAC
[Arimidex, Tamoxifen Alone or in Combination], a trial of a
novel adjuvant hormonal therapy in early breast cancer
[4,5]), such examples are few and far between, particularly
if the commercial benefits are small. It seems that the most
likely source of this extra resource will be grant-funding
bodies such as the charitable organizations. Already
overstretched budgets will have to be stretched further to
meet the new legislative requirements. This will ultimately147
mean that we will see fewer of the smaller ‘pilot’ studies
and the trend will be toward larger, multicentred trials, but
fewer of them.
Another concern is that the legislation brought about by
the CTD will focus the ‘mindset’ of the various agencies
concerned on clinical trials of medicinal products, to the
detriment of work that falls outside of this definition. Will a
regulatory agency require the name of a sponsor for a
study setting up a tumour bank to investigate translational
work? How closely will an ethics committee look at an
application performing dietary studies on healthy
volunteers? Would the cranberry juice used in a trial to
investigate its effects on urinary tract infections have to
pass the stringent requirements of Good Manufacturing
Practice, and will there be an expectation that adverse
events will be reported?
The CTD has been ‘in the pipeline’ for more than 3 years.
Unfortunately, many academic clinical trialists across
Europe have only recently woken up to the changes that
the CTD will bring, which had to come sooner or later. For
better or for worse, on Saturday 1 May 2004 the rules will
alter significantly. The challenge we all face is to find
innovative ways of dealing with these changes, or the
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